- Markets
- Chemicals
- EIKO
EIKO
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Eiko Lifesciences Announces Strategic Diversification Into Logistics And Container Management
Dec 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ANNOUNCES STRATEGIC DIVERSIFICATION INTO LOGISTICS AND CONTAINER MANAGEMENT
EIKOVIVIFY LOGISTICS ENTERS LONG-TERM SERVICE CONTRACT WITH S J LOGISTICS
EIKOVIVIFY LOGISTICS BUYS 1,000 CONTAINERS UNDER COLLABORATION
Source text: ID:nBSE5qSlrS
Further company coverage: EIKO.BO
(([email protected];;))
Dec 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ANNOUNCES STRATEGIC DIVERSIFICATION INTO LOGISTICS AND CONTAINER MANAGEMENT
EIKOVIVIFY LOGISTICS ENTERS LONG-TERM SERVICE CONTRACT WITH S J LOGISTICS
EIKOVIVIFY LOGISTICS BUYS 1,000 CONTAINERS UNDER COLLABORATION
Source text: ID:nBSE5qSlrS
Further company coverage: EIKO.BO
(([email protected];;))
Eiko Lifesciences To Enter Into Definitive Business Agreement With Vivacious Pharmatex
Jan 25 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
TO ENTER INTO DEFINITIVE BUSINESS AGREEMENT WITH VIVACIOUS PHARMATEX
Source text for Eikon: ID:nBSE45Bhpw
Further company coverage: EIKO.BO
(([email protected];))
Jan 25 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
TO ENTER INTO DEFINITIVE BUSINESS AGREEMENT WITH VIVACIOUS PHARMATEX
Source text for Eikon: ID:nBSE45Bhpw
Further company coverage: EIKO.BO
(([email protected];))
Eiko Lifesciences Approved Right Entitlement Ratio Of 2 Share For Every 3 Shares Held
June 30 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
APPROVED RIGHT ENTITLEMENT RATIO OF 2 SHARE FOR EVERY 3 SHARES HELD
APPROVED RIGHT ISSUE PRICE OF 45 RUPEES PER SHARE
Source text for Eikon: ID:nBSE4QrjDq
Further company coverage: EIKO.BO
(([email protected];;))
June 30 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
APPROVED RIGHT ENTITLEMENT RATIO OF 2 SHARE FOR EVERY 3 SHARES HELD
APPROVED RIGHT ISSUE PRICE OF 45 RUPEES PER SHARE
Source text for Eikon: ID:nBSE4QrjDq
Further company coverage: EIKO.BO
(([email protected];;))
Eiko Lifesciences Enters Into A Share Subscription Agreement With Reflux Pharmaceuticals Pvt Ltd
May 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ENTERED INTO A SHARE SUBSCRIPTION AGREEMENT WITH REFLUX PHARMACEUTICALS PVT LTD
AGREEMENT FOR ACQUISITION OF UP TO 1.9 MILLION EQUITY SHARES BEING 25.01% EQUITY STAKE
CONSIDERATION FOR 70 MILLION RUPEES
Source text for Eikon: ID:nBSE7d8p65
Further company coverage: EIKO.BO
(([email protected];))
May 18 (Reuters) - Eiko Lifesciences Ltd EIKO.BO:
ENTERED INTO A SHARE SUBSCRIPTION AGREEMENT WITH REFLUX PHARMACEUTICALS PVT LTD
AGREEMENT FOR ACQUISITION OF UP TO 1.9 MILLION EQUITY SHARES BEING 25.01% EQUITY STAKE
CONSIDERATION FOR 70 MILLION RUPEES
Source text for Eikon: ID:nBSE7d8p65
Further company coverage: EIKO.BO
(([email protected];))
Events:
Rights
Dividend
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Eiko Lifesciences do?
Eiko Lifesciences Limited operates as an investment company, dealing in various financial instruments like shares, bonds, and securities, both domestically and internationally.
Who are the competitors of Eiko Lifesciences?
Eiko Lifesciences major competitors are Sunil Healthcare, TECIL Chem & Hydro, Malpani Pipes&Fittin, Vasundhara Rasayans, Polylink Polymers, Shree Hari Chem, Unilex Colours &Chem. Market Cap of Eiko Lifesciences is ₹75 Crs. While the median market cap of its peers are ₹73 Crs.
Is Eiko Lifesciences financially stable compared to its competitors?
Eiko Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Eiko Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Eiko Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Eiko Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Eiko Lifesciences balance sheet?
Balance sheet of Eiko Lifesciences is strong. But short term working capital might become an issue for this company.
Is the profitablity of Eiko Lifesciences improving?
The profit is oscillating. The profit of Eiko Lifesciences is ₹0.87 Crs for TTM, ₹0.75 Crs for Mar 2024 and ₹0.77 Crs for Mar 2023.
Is the debt of Eiko Lifesciences increasing or decreasing?
Yes, The debt of Eiko Lifesciences is increasing. Latest debt of Eiko Lifesciences is -₹2.71 Crs as of Sep-24. This is greater than Mar-24 when it was -₹26.68 Crs.
Is Eiko Lifesciences stock expensive?
Eiko Lifesciences is not expensive. Latest PE of Eiko Lifesciences is 65.48, while 3 year average PE is 73.84. Also latest EV/EBITDA of Eiko Lifesciences is 36.75 while 3yr average is 46.39.
Has the share price of Eiko Lifesciences grown faster than its competition?
Eiko Lifesciences has given lower returns compared to its competitors. Eiko Lifesciences has grown at ~-10.57% over the last 2yrs while peers have grown at a median rate of 28.74%
Is the promoter bullish about Eiko Lifesciences?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 36.23% and last quarter promoter holding is 31.27%.
Are mutual funds buying/selling Eiko Lifesciences?
There is Insufficient data to gauge this.